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1. Overview 
Acute Coronary Syndrome (ACS) represents a continuous spectrum of disease including 
Unstable Angina (UA), acute non-ST elevation myocardial infarction (NSTEMI), and acute 
ST elevation myocardial infarction (STEMI). In spite of major advances in prevention and 
treatment, Acute Coronary Syndrome remains a leading cause of death as well as a major 
cause of hospital admissions both within Europe and worldwide.[1-3] 
Recent advances have allowed for early detection and disposition of patients with Acute 
Coronary Syndrome. The first step in the management of patients with ACS is prompt 
recognition. The diagnosis of ACS is largely based on the history, the electrocardiogram 
(ECG) and changes in cardiac biomarkers. It is a universally acknowledged fact that history 
remains the most essential tool in directing the need for further workup which includes 
serial ECGs and measurement of cardiac biomarkers. 
2. Diagnostic challenges 
The ECG is an important diagnostic and risk stratification tool. Most patients who have 
UA/NSTEMI have some ECG changes, although the ECG may be normal in 1% to 6% of 
patients who have NSTEMI and in approximately 4% of patients who have UA.[4]ST 
elevation myocardial infarction (STEMI) is diagnosed by the symptoms and the 
characteristic ST elevation on the ECG. The other two variants of ACS, non-ST elevation 
myocardial infarction and unstable angina are differentiated from each other by the 
presence of positive cardiac biomarker in the former and the treatment varies 
accordingly.[5-7] 
Of the number of available markers and assays that detect myocardial necrosis, the cardiac 
troponins T and I and the creatinine kinase–MB (CK-MB) isoform are the most commonly 
used, with troponins gaining acceptance as the markers of choice in ACS. These have 
achieved an important role in diagnostic, prognostic, and treatment pathways by virtue of 
their high degree of sensitivity and specificity and their relative ease of use and 
interpretation. However, troponins are detectable only 6 hours after myocardial injury and 
are measurable for up to 2 weeks. 
For a patient presenting with a suspected acute MI, the characteristics of the chest pain and 
the ECG findings permit initial risk stratification. The gold standard in the care of a patient 
www.intechopen.com
  
Acute Coronary Syndromes 
 
164 
with cardiac chest pain is that an ECG and an abbreviated history and physical examination 
be obtained within 10 minutes of patient arrival.[8] 
The early diagnosis of acute myocardial infarction (AMI) is however sometimes difficult due 
to: [9] 
1. Equivocal electrocardiogram (ECG) changes and other conditions with ECG changes 
that mimic acute myocardial infarction. Atypical chest pains with many differentials 
confuse to make a diagnosis. 
2. Acute myocardial infarction patients without ST-segment elevation. 
3. Delayed liberation and detection of cardiac markers of myocardial necrosis such as 
troponin and creatine kinase (CK). 
Cardiac troponin is frequently not detected until after 4-6 hours and in many cases, repeated 
measurement is needed 8-12 hours after admission. The importance of early risk 
stratification in the management of acute myocardial infarction is emphasized in the 
American Heart Association task force guidelines.[10]Risk stratification is an important 
objective in the evaluation of patients with ACS. The presence of positive biomarkers 
indicates higher risk and worse prognosis.[11] 
When initiating reperfusion therapy, door-to-needle time of less than or equal to 30 minutes 
for initiation of fibrinolytic therapy and a door-to-balloon time of less than or equal to 90 
minutes for percutaneous coronary perfusion is the standard of care.[12-14]Although, more 
and more hospitals are meeting this benchmark, diagnosing and excluding ACS often poses 
a diagnostic challenge to the clinicians.[15]A misdiagnosis may lead to considerable increase 
in morbidity and mortality. An ideal marker which can predict the onset of the disease, 
could aid in reducing the deaths due to ACS. 
3. Cardiac biomarkers 
Acute myocardial infarction refers to irreversible myocardial necrosis caused by an 
imbalance between oxygen supply and demand. In 75% cases, plaque rupture or erosion 
leading to thrombus formation are the causes of acute coronary syndromes. Early diagnosis 
and subsequent reperfusion therapies within 4 to 6 hours of onset of symptoms can salvage 
myocardium at risk. Therefore, optimal markers of myocardial necrosis need to be rapidly 
detectable in blood. 
Myocardial injury causes release into the extracellular space of intracellular constituents 
including detectable levels of a variety of biologically active cytosolic and structural proteins 
such as troponin, creatine kinase, myoglobin, lactate dehydrogenase, etc. 
Cardiac biomarkers have characteristic release and clearance kinetics. However, the time to 
presentation and comorbidities that affect clearance may confound the interpretation of 
biomarkers. Myoglobin is the earliest biochemical marker of myocardial cell damage, and it 
is detectable in blood within 1 to 2 hours of myocyte damage. Blood levels of CK-MB may 
be detectable in blood after 4 to 6 hours of myocardial ischemia. [16] Cardiac troponins are 
elevated within 4 to 12 hours of symptom onset and remain elevated for 4 to 10 days. [17] 
Based on these patterns of release and clearance, a diagnostic algorithm of serial biomarker 
measurements has been developed. Serial sampling of multiple cardiac markers beginning 
at the time of presentation is recommended currently. The sensitivity of serial 
measurements of multiple markers nears 100%, whereas the sensitivity of a single 
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measurement of any biomarker at the time of presentation is poor. The recommended time 
between the first and second blood draw is 6 to 7 hours. [18] If cardiac marker levels are not 
elevated but clinical suspicion remains high, a third set of markers should be drawn at 12 to 
24 hours after presentation. [19] The markers currently used in this multimarker approach are 
myoglobin, CKMB, and troponin. 
3.1 Myoglobin 
Myoglobin is a heme protein found in the cytoplasm of cardiac and skeletal muscle cells that 
rises most rapidly after myocardial injury but is not cardiac-specific. [16] Myoglobin levels 
are frequently elevated in patients who have renal failure, skeletal muscle injury, trauma, 
and other diseases. Myoglobin is not used in most hospital laboratories. 
3.2 Creatine kinase-MB isoform 
CK-MB is an enzyme present primarily in cardiac muscle and active in energy 
generation. CK-MB is released rapidly after myocardial injury and is more cardiac-
specific than myoglobin. However, CK-MB also comprises up to 5% of skeletal muscle 
and can be elevated in noncardiac disease states. Before the use of troponin, CK-MB was 
the gold standard for the biochemical diagnosis of AMI. CK-MB is released early during 
AMI, and it plays an important role in defining infarct size, infarct expansion, and 
reinfarction.[20] 
3.3 Cardiac troponins 
Cardiac troponins and tropomyosin form the thin filament component of the contractile 
structure in striated muscle. Troponins are released into the blood stream following 
irreversible ischemic myocardial cell injury and remain elevated for a prolonged time. 
There is no clinical difference between TnT and TnI for diagnosing cardiac necrosis. There 
are separate cardiac and skeletal isoforms of both TnI and TnT, allowing for the 
development of highly cardiac-specific assays. [17, 21] Troponin assays can detect as little as 
1 g of myocardial tissue necrosis, and even minute elevations in cardiac troponins have 
been associated with myocardial necrosis and increased rate of short- and long-term 
mortality. [19,22-24] 
Cardiac troponins have been studied in symptomatic and asymptomatic patients who have 
renal dysfunction. It is important that emergency physicians include the patient’s history 
and physical examination when considering an elevated troponin level in patients who have 
renal dysfunction. In patients in whom acute coronary syndrome is not suspected, renal 
failure may be associated with chronic elevations of TnI and TnT, without evidence of acute 
myocardial necrosis. However, an acute increase from baseline troponin levels may be 
associated with increased mortality[25, 26] 
Therefore, baseline troponin levels are helpful when differentiating between acute and 
chronic elevations in cardiac troponins. Elevated levels of cardiac troponins in patients who 
have renal dysfunction may be attributable to decreased renal clearance and increased 
release from cytoplasm because of the loss of membrane integrity. TnT is of higher 
molecular weight and is more commonly present in the free, unbound form in the 
cytoplasm, potentially explaining why TnT is more frequently elevated than TnI. [25] A study 
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of asymptomatic patients who had renal failure did not show TnI levels to be elevated in 
this population. The previously noted false-positive TnI results in patients who have renal 
failure were measured during acute disease states, including sepsis or pulmonary embolism, 
which may independently cause elevated troponin levels. [27] 
In symptomatic patients who have chest pain and renal dysfunction, elevated levels of 
cardiac troponin predict patients at an increased risk for adverse cardiovascular outcomes. 
In a study of 7033 patients who had suspected acute coronary syndromes, the elevated 
levels of TnT were predictive of death or myocardial infarction across the spectrum of 
creatinine clearance. [28] 
Despite the value of cardiac troponin as a very sensitive marker for myocardial damage, 
elevated troponin levels do not reflect the mechanism of damage and should not be used 
alone to diagnose myocardial infarction. Troponin levels may be elevated in patients who 
have myocarditis, pericarditis, decompensated heart failure, and septic shock. The use of 
troponin measurements as a screening tool in patients whose conditions have a low 
suspicion for ACS lowers the sensitivity and positive predictive value to 47% and 19%, 
respectively. A high sensitive troponin could be available in future to turn out an ideal 
biomarker for ACS. [29] 
4. Heart-type fatty acid-binding protein 
Heart-type fatty acid-binding protein (h-FABP) has been researched since 1988, due to its 
high potential as an early marker for myocardial infarction. It bears considerable 
resemblance to myoglobin in terms of size, location within the cell, release and clearance 
kinetics. It is a relatively low molecular mass cytoplasmic protein (15 kDa) available in 
abundance in myocardial tissue. [30-32]It is important for myocardial homeostasis since 50 – 
80% of the heart’s energy is provided by lipid oxidation and h-FABP ensures intracellular 
transport of insoluble fatty acids. It is released from the heart during cell necrosis, it diffuses 
much more rapidly than troponins through the interstitial space and appears in the 
circulation as early as 90 minutes after the onset of symptoms, reaching its peak within 6 
hours and clearing within 24 hours. 
This combination of early h-FABP release after symptom onset, rapid kidney clearance from 
the circulation and high cardiac specificity suggests great potential for its clinical use.[30-
32]Therefore,it can be derived that h-FABP may not only be of value in detecting myocardial 
injury in the early hours of the insult but may also be ideal for the diagnosis of reinfarctions. 
H-FABP has been found to be superior to troponins due to its higher sensitivity.[33, 34]A 
recent study showed h-FABP had a sensitivity of 75.76% and a specificity of 96.97% 
compared with 58.59% and 98.94% for cTnT and 68.69% and 97.54% for CK-MB in the initial 
6 hours after the onset of chest pain. [35]Recent data also suggests h-FABP may provide some 
prognostic information which appears superior to that of troponins. [36].   
4.1 h-FABP in the pre-hospital setting 
There is some evidence to suggest the utility of h-FABP in the pre-hospital 
setting.[37]According to the literature, early assessment of H-FABP in patients presenting 
with chest pain improves the diagnosis of an ongoing myocardial infarction. An h-FABP 
self-testing kit can be helpful in the pre-hospital setting. Though an h-FABP testing kit (h-
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FABP Quanta) is used for the quantitative measurement, especially in next one hour of the 
initial testing to see if there is a rise of titre. This kit is more useful in emergency 
department/CCU and ICU setting. ConformitéEuropéenne (CE) certification approving it 
for sale in the European Union member countries. 
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